SecBot SecBot
144 ·Filed Nov 2, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 3/10
Horizondays Processed14d 7h ago SEC0001950047-26-010587
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The 10b5-1 plan context and the consistent daily selling pattern since August 2026 suggest this is a scheduled diversification program rather than a reactive insider sale. Monitor for any change in the pace or size of daily sales, which could signal a shift in insider sentiment.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$601.32
T+0 close · Nov 2, 2026 · via day close
Latest settled
−2.11%
T+5 · $588.61 · next T+20 in 15d
Vs SPY
−1.53%
α at T+5
Latest observation
−2.00%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $601.32entry
  2. T+1 · 13d ago +1.19%α −0.46% · $608.49
  3. T+5 · 7d ago −2.11%α −1.53% · $588.61
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director and officer Martine Rothblatt filed a Form 144 notice of intent to sell 119,410 shares of United Therapeutics common stock, with an estimated aggregate market value of approximately $71.5 million. The filing indicates these sales are part of a pre-arranged 10b5-1 trading plan, and Rothblatt has been executing daily sales of 9,500 shares since August 2026 under that plan.

Key Facts

  • Martine Rothblatt, a director and officer of United Therapeutics, filed a Form 144 on 2026-11-02.
  • The proposed sale covers 119,410 shares of common stock, with an estimated market value of $71,493,155.20.
  • The filing explicitly references a 10b5-1 trading plan, with daily sales of 9,500 shares occurring since August 2026.
  • Rothblatt has been executing these sales consistently from August through October 2026, with each day's sale valued between approximately $4.5M and $5.7M.
  • The filing notes that shares are being sold by Martine Rothblatt and/or the Martine Rothblatt Property Management Trust, which is beneficially owned by Rothblatt.

Financial Impact

Proposed sale of 119,410 shares valued at approximately $71.5 million, representing about 0.28% of the $25.5B market cap.

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur or may differ in size.
  • Insider selling, even under a 10b5-1 plan, can create overhang perception if the market views the volume as large relative to average daily trading volume.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010587
Document: 0001950047-26-010587-index.html0001950047-26-010587
Document: 0001950047-26-010587.txt0001950047-26-010587

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens in 8h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026